Core Viewpoint - MacKenzie Realty Capital, Inc. has announced a 1-for-10 reverse stock split to increase its common stock price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will take effect at 5:01 p.m. Eastern Standard Time on August 4, 2025, with trading on a split-adjusted basis starting August 5, 2025 [1]. - The split will convert ten existing shares into one new share, reducing the number of outstanding shares from approximately 16,760,978 to about 1,676,098 [2]. - Stockholders entitled to fractional shares will receive cash equivalent to the fractional amount multiplied by the closing price on August 1, 2025 [2]. Group 2: Administrative Aspects - Computershare, Inc. will serve as the exchange agent for the reverse stock split, and stockholders will not need to take action to receive their post-split shares [3]. - The CUSIP number for the company will change to 55453W501 effective at the time of the split [4]. Group 3: Company Overview - MacKenzie Realty Capital, Inc. is a West Coast-focused REIT, aiming to invest at least 80% of its total assets in real property, with a portfolio consisting of approximately 50% multifamily and 50% boutique class A office properties [5]. - The company has maintained a dividend payout every year since its inception and currently holds interests in 4 multifamily properties and 8 office properties, along with 2 multifamily developments [5].

Core Viewpoint - Opendoor Technologies Inc. has announced the adjournment of its Special Meeting of Stockholders to August 27, 2025, to allow more time to assess market conditions and the company's stock price [1][5]. Proposal and Compliance - The Special Meeting was originally convened to consider two proposals regarding a discretionary reverse stock split of the company's common stock, which would only be pursued if deemed beneficial by the Board of Directors [2]. - The company received a notice from Nasdaq in May indicating non-compliance with listing rules due to its stock price being below $1.00 per share for 30 consecutive business days [3]. - To regain compliance, Opendoor's stock price must be at least $1.00 per share for a minimum of 10 consecutive business days by November 24, 2025 [4]. Meeting Details - The adjourned Special Meeting will continue to be held online, and stockholders are encouraged to vote during the adjournment period [6][7]. - The record date for stockholders entitled to vote remains June 4, 2025 [7].

Core Viewpoint - Vaxart, Inc. is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirements following a trading suspension due to non-compliance [2][3][4] Group 1: Reverse Stock Split Proposal - The preliminary proxy statement includes a proposal for a reverse stock split with a ratio of not less than 1-for-5 and not more than 1-for-20 [9] - The proposal aims to reduce the number of authorized shares of common stock in proportion to the reverse stock split [4][9] - The Board of Directors believes that compliance with Nasdaq listing requirements is essential for liquidity and capital raising [3] Group 2: Stockholder Engagement - A special meeting of stockholders is scheduled for September 5, 2025, to discuss the reverse stock split proposal [5] - Management plans to hold a live stockholder fireside chat to address questions and explain the necessity of the reverse stock split [3][8] Group 3: Company Overview - Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using a proprietary delivery platform [6] - The company's vaccine candidates include those for coronavirus, norovirus, influenza, and a therapeutic vaccine for human papillomavirus (HPV) [6]

Core Insights - Lucid Motors received a significant boost with Uber Technologies announcing a $300 million investment to form a robotaxi partnership, leading to a stock increase of over 40% [1][3] - The partnership aims to deploy a fleet of 20,000 Lucid vehicles over the next six years, utilizing Lucid's Gravity SUV and Nuro's level 4 autonomy system [4][6] - Lucid's recent developments, including the potential reverse stock split, are aimed at enhancing its attractiveness to institutional investors [9][12] Investment Partnership - The collaboration with Uber involves creating a new robotaxi service that leverages Lucid's advanced vehicle technology and Uber's extensive global network [3][7] - The first prototype of the Lucid-Nuro robotaxi is already operational, indicating progress in the partnership [4] - This investment validates Lucid's technology and positions it favorably in the autonomous vehicle market, potentially increasing demand for its products [9][13] Production and Market Strategy - Lucid aims to deliver approximately 20,000 vehicles in 2025, a significant increase from the 6,500 vehicles delivered in the first half of the year [6] - The partnership with Uber is seen as a critical step in proving Lucid's technology and market demand, especially in comparison to competitors like Rivian [7][8] Reverse Stock Split - Lucid has filed for a reverse stock split at a ratio of 1:10, which will consolidate shares and increase the trading price without changing market capitalization [10][11] - This move is intended to make Lucid's stock more appealing to larger institutional investors who often have minimum price thresholds for investment [12] - While reverse stock splits are generally viewed negatively, Lucid's situation does not indicate immediate financial distress [11][13]

Core Viewpoint - Generation Bio Co. announced a 1-for-10 reverse stock split to increase the per-share market price and regain compliance with Nasdaq listing requirements [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will be effective at 5:00 pm Eastern Time on July 21, 2025, and trading on a split-adjusted basis will begin on July 22, 2025 [1][2]. - The number of issued and outstanding shares will decrease from approximately 67.3 million to approximately 6.7 million [3]. - No fractional shares will be issued; instead, stockholders will receive cash payments for any fractional shares [4]. Group 2: Company Background - Generation Bio is focused on developing therapeutics for T cell-driven autoimmune diseases using cell-targeted lipid nanoparticles to deliver small interfering RNA to T cells [7]. - The company's innovative approach aims to address historically undruggable disease-driving genes in autoimmunity [7].

Group 1 - Lucid's stock increased by 46.72% in premarket trading following Uber's announcement of a $300 million investment in the electric vehicle maker as part of a six-year robotaxi partnership [1][4] - Under the agreement, Uber will deploy at least 20,000 Lucid vehicles equipped with Nuro's self-driving technology over a six-year period, with the first robotaxis expected to launch in a major U.S. city next year [3][4] - The partnership marks a significant shift for Lucid from focusing on luxury consumer vehicles to entering the commercial robotaxi market [5] Group 2 - Lucid's first robotaxi prototype is currently being tested at Nuro's Las Vegas proving grounds, with the vehicles set to be owned and operated by Uber or its fleet partners [6] - Lucid filed a preliminary proxy statement with the SEC regarding a special stockholders' meeting to authorize a 1-for-10 reverse stock split, which the company believes will make its common stock more attractive to investors [7] - The reverse stock split will not affect stockholders' ownership interests or voting power, except for potential cash payments for fractional shares, and requires majority approval from votes cast at the special stockholders' meeting [8]

Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) today announced the results of the annual meeting of its stockholders held on July 15, 2025. At the annual meeting, Ikena’s stockholders voted in favor of all proposals, including a proposal approving the previously announced merger with Inmagene Biopharmaceuticals (“Inmagene”). The mer ...

Core Viewpoint - Passage Bio, Inc. has announced a reverse stock split at a ratio of 1-for-20 to comply with Nasdaq's minimum bid price requirement of $1.00 per share, effective July 14, 2025 [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of outstanding shares from approximately 62,405,898 to about 3,120,295 [2]. - Proportionate adjustments will be made to the exercise prices and number of shares underlying the Company's equity awards and incentive plans [2]. - The reverse stock split will not change the number of authorized shares or the par value per share [2]. Group 2: Stockholder Information - Registered stockholders holding shares in book-entry form will not need to take action to receive post-split shares [3]. - Stockholders with shares in brokerage accounts will have their positions automatically adjusted, with no action required on their part [3]. - No fractional shares will be issued; stockholders entitled to fractional shares will receive the nearest whole share [3]. Group 3: Company Overview - Passage Bio is a clinical-stage genetic medicines company focused on developing therapies for neurodegenerative diseases [4]. - The lead product candidate, PBFT02, aims to treat conditions like frontotemporal dementia by elevating progranulin levels [4].

Core Points - CLS Holdings USA, Inc. announced a reverse stock split of one post-Consolidation Share for every 4,000,000 pre-Consolidation Shares, approved by 94.27% of Stockholders [1] - The effective date of the Consolidation is set for July 11, 2025, following unanimous approval from the Board of Directors [2] - Stockholders will receive a cash payment of $0.037 per pre-Consolidation Share for any fractional shares resulting from the Consolidation [3] - CLS has applied for voluntary delisting from the Canadian Securities Exchange, with the delisting expected to occur on the same date as the effective date of the Consolidation [4] - CLS Holdings USA Inc. operates as a diversified cannabis company, focusing on integrated cannabis production and retail, utilizing a patented method for cannabinoid extraction [5]

Core Viewpoint - MacKenzie Realty Capital, Inc. has announced a 1-for-10 reverse stock split to increase its share price and meet Nasdaq listing requirements [1][2]. Group 1: Reverse Stock Split Details - The reverse stock split will convert ten existing shares into one new share, reducing the total shares outstanding from approximately 15,781,930 to about 1,578,192 [2]. - No fractional shares will be issued; instead, stockholders entitled to a fractional share will receive cash equivalent to the fraction multiplied by the closing price prior to the split [2]. - The effective date of the reverse stock split will be announced at least two business days before implementation [4]. Group 2: Stockholder Information - Stockholders of record will not need to take action to receive post-split shares, as their positions will be automatically adjusted [3]. - Stockholders holding shares through banks or brokers should check with their respective institutions for specific procedures regarding the reverse stock split [3]. Group 3: Company Overview - MacKenzie Realty Capital, founded in 2013, is a West Coast-focused REIT aiming to invest at least 80% of its total assets in real property, with a portfolio consisting of approximately 50% multifamily and 50% boutique class A office properties [5]. - The company has consistently paid dividends since its inception and currently holds interests in 4 multifamily properties and 8 office properties, along with 2 multifamily developments [5].